Singh, Dave http://orcid.org/0000-0001-8918-7075
Han, MeiLan K. http://orcid.org/0000-0002-9095-4419
Hawkins, Nathaniel M. http://orcid.org/0000-0003-1286-2014
Hurst, John R. http://orcid.org/0000-0002-7246-6040
Kocks, Janwillem W. H. http://orcid.org/0000-0002-2760-0693
Skolnik, Neil http://orcid.org/0000-0002-5085-4771
Stolz, Daiana http://orcid.org/0000-0003-0099-882X
El Khoury, Jad
Gale, Chris P. http://orcid.org/0000-0003-4732-382X
Funding for this research was provided by:
AstraZeneca
Article History
Received: 23 February 2024
Accepted: 22 March 2024
First Online: 25 April 2024
Declarations
:
: Dave Singh has received consultancy fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, EpiEndo, Genentech, GlaxoSmithKline, Glenmark, Gossamer Bio, Kinaset Therapeutics, Menarini, Novartis, Orion, Pulmatrix, Sanofi, Teva, Theravance Biopharma and Verona Pharma. MeiLan K. Han reports personal fees from Aerogen, Altesa BioPharma, Amgen, Apreo Health, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, DevPro, Genentech, GlaxoSmithKline, Integrity, Novartis, Teva, MDBriefCase, Medscape, Medwiz, Merck, Mylan, NACE, Polarian, Pulmonx, Regeneron, Roche, RS BioTherapeutics, Sanofi, UpToDate and Verona Pharma; has received either in-kind research support or funds paid to the institution from the American Lung Association, AstraZeneca, Biodesix, Boehringer Ingelheim, the COPD Foundation, Gala Therapeutics, the National Institutes of Health, Novartis, Nuvaira, Sanofi and Sunovion; has participated in data safety monitoring boards for Medtronic and Novartis with funds paid to the institution; and has received stock options from Altesa BioPharma and Meissa Vaccines. Nathaniel M. Hawkins reports grants, speaker bureau, advisory board and consultancy honoraria from pharmaceutical companies including AstraZeneca, Bayer, Boehringer Ingelheim, Novartis and Servier. John R. Hurst has received speaker/consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Takeda. Janwillem W.H. Kocks reports grants, personal fees and non-financial support from AstraZeneca; grants, personal fees and non-financial support from Boehringer Ingelheim; grants and personal fees from Chiesi; grants, personal fees and non-financial support from GlaxoSmithKline; non-financial support from Mundi Pharma; grants and personal fees from Teva; personal fees from MSD; personal fees from Covis Pharma; personal fees from ALK-Abelló; and grants from Valneva outside the submitted work; holds < 5% shares of Lothar Medtec GmbH and 72.5% of shares in the General Practitioners Research Institute. Neil Skolnik has received speaker/consultancy fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Idorsia, Lilly, Merck, Novartis, Sanofi, Sanofi Pasteur and Teva; and research funding from AstraZeneca, Bayer, GlaxoSmithKline, Novo Nordisk and Sanofi. Daiana Stolz is the current GOLD representative for Switzerland and has received speaker/consultancy fees from Almirall, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, MSD, Novartis, Sanofi and Vifor; and research grants from AstraZeneca and Curetis. Jad El Khoury is an employee of AstraZeneca and holds shares and stock options in the company. Chris P. Gale has received speaker fees from AstraZeneca, Medisetter, Menarini, Novartis, Raisio Group, Wondr Medical, Zydus; advisory board and consultancy honoraria from AI Nexus, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiomatics, Chiesi, Daiichi Sankyo, General Practitioners Research Institute, iRhythm, Menarini, Novartis, Organon, Phoenix Group; research grants from Abbott Diabetes, Bristol Myers Squibb, the British Heart Foundation, Horizon 2020, and the National Institute for Health and Care Research.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.